Showing results (91-100 of 432) with videos related to

Sort By:
Pageof 44
Tumori|August 8, 2007
Merkel cell carcinoma after liver transplantation: a case reportEmilio Bajetta, Marco Platania, Laura Catena, et al.
Cancers|August 7, 2021
Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell CarcinomaPierangela Sepe, Arianna Ottini, Chiara Carlotta Pircher, et al.
Therapeutic Advances in Urology|July 11, 2015
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinomaElisa Zanardi, Elena Verzoni, Paolo Grassi, et al.
Cancer Biology & Therapy|July 25, 2012
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistantAmelia Altavilla, Roberto Iacovelli, Giuseppe Procopio, et al.
Clinical Genitourinary Cancer|October 11, 2025
Bone Health and Body Composition as Predictive and Prognostic Markers in Metastatic Castration-resistant Prostate Cancer: A Meet-URO Narrative ReviewAnna Amela Valsecchi, Maria Concetta Cursano, Francesco Pantano, et al.
Future Oncology (London, England)|July 25, 2019
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO GroupGiuseppe Procopio, Sandro Pignata, Amelia Altavilla, et al.
Neuroendocrinology|July 26, 2017
Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year UpdateEmilio Bajetta, Laura Catena, Sara Pusceddu, et al.
Clinical Genitourinary Cancer|February 27, 2018
Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world AnalysisRaffaele Ratta, Elena Verzoni, Massimo Di Maio, et al.
Tumori|January 31, 2007
Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumorsLeonardo Ferrari, Silvia Della Torre, Paola Collini, et al.
Expert Review of Anticancer Therapy|June 10, 2026
Local treatment of the primary tumour in mHSPC in the ARPI era: incremental value or overtreatment?Simone Rota, Melanie Claps, Eleonora Gusmaroli, et al.
Pageof 44